The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hosseinkhani, H., & Tabata, Y. (2004) · Journal of Controlled Release · doi:10.1016/s0168-3659(04)00102-6 · Cited by 39
RetractedPierschbacher, M. D., & Ruoslahti, E. (1984) · Nature · doi:10.1038/309030a0 · Cited by 3,658
Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment
Wickham, T. J., Mathias, P., Cheresh, D. A., & Nemerow, G. R. (1993) · Cell · doi:10.1016/0092-8674(93)90231-e · Cited by 2,199
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Anti-cancer activity of targeted pro-apoptotic peptides
Ellerby, H. M., Arap, W., Ellerby, L. M., Kain, R., Andrusiak, R., Rio, G. D., Krajewski, S., Lombardo, C. R., Rao, R., Ruoslahti, E., et al. (1999) · Nature Medicine · doi:10.1038/12469 · Cited by 936
Schiffelers, R. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh140 · Cited by 901
Self-citationTumor Regression by Targeted Gene Delivery to the Neovasculature
Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., & Cheresh, D. A. (2002) · Science · doi:10.1126/science.1070200 · Cited by 858
Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging
Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D., & Li, K. C. P. (1998) · Nature Medicine · doi:10.1038/nm0598-623 · Cited by 850
N -Methylated Cyclic RGD Peptides as Highly Active and Selective α V β 3 Integrin Antagonists
Dechantsreiter, M. A., Planker, E., Mathä, B., Lohof, E., Hölzemann, G., Jonczyk, A., Goodman, S. L., & Kessler, H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm970832g · Cited by 838
Grant, D. S., Tashiro, K.-I., Segui-Real, B., Yamada, Y., Martin, G. R., & Kleinman, H. K. (1989) · Cell · doi:10.1016/0092-8674(89)90945-8 · Cited by 740
Cited by
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis
Danhier, F., Le Breton, A., & Préat, V. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3002733 · Cited by 955
Nanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 878
PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time
Kooijmans, S. A. A., Fliervoet, L. A. L., van der Meel, R., Fens, M. H. A. M., Heijnen, H. F. G., van Bergen en Henegouwen, P. M. P., Vader, P., & Schiffelers, R. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.009 · Cited by 625
Self-citationExosome mimetics: a novel class of drug delivery systems
Schiffelers, R., Kooijmans, S., Vader, van Dommelen, & Solinge, V. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s29661 · Cited by 512
Self-citationCancer Treatment Using Peptides: Current Therapies and Future Prospects
Thundimadathil, J. (2012) · Journal of Amino Acids · doi:10.1155/2012/967347 · Cited by 491
Prodrug Strategies in Anticancer Chemotherapy
Kratz, F., Müller, I. A., Ryppa, C., & Warnecke, A. (2008) · ChemMedChem · doi:10.1002/cmdc.200700159 · Cited by 486
Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis
Murphy, E. A., Majeti, B. K., Barnes, L. A., Makale, M., Weis, S. M., Lutu-Fuga, K., Wrasidlo, W., & Cheresh, D. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803728105 · Cited by 455
Recent progress in development of siRNA delivery vehicles for cancer therapy
Kim, H. J., Kim, A., Miyata, K., & Kataoka, K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.011 · Cited by 424
Eskandari, S., Guerin, T., Toth, I., & Stephenson, R. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.013 · Cited by 381
Anti-angiogenesis therapy in cancer: Current challenges and future perspectives
Shojaei, F. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.008 · Cited by 348
Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel
Danhier, F., Vroman, B., Lecouturier, N., Crokart, N., Pourcelle, V., Freichels, H., Jérôme, C., Marchand-Brynaert, J., Feron, O., & Préat, V. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.08.011 · Cited by 335
αVβ3 Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-tumor Efficacy of a Pt(IV) Prodrug
Graf, N., Bielenberg, D. R., Kolishetti, N., Muus, C., Banyard, J., Farokhzad, O. C., & Lippard, S. J. (2012) · ACS Nano · doi:10.1021/nn301148e · Cited by 327
Passive versus Active Tumor Targeting Using RGD- and NGR-Modified Polymeric Nanomedicines
Kunjachan, S., Pola, R., Gremse, F., Theek, B., Ehling, J., Moeckel, D., Hermanns-Sachweh, B., Pechar, M., Ulbrich, K., Hennink, W. E., et al. (2014) · Nano Letters · doi:10.1021/nl404391r · Cited by 317
Lee, M. H., Kim, J. Y., Han, J. H., Bhuniya, S., Sessler, J. L., Kang, C., & Kim, J. S. (2012) · Journal of the American Chemical Society · doi:10.1021/ja303998y · Cited by 309
Peptide-based cancer therapy: Opportunity and challenge
Wu, D., Gao, Y., Qi, Y., Chen, L., Ma, Y., & Li, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.05.002 · Cited by 306
Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles
Han, H. D., Mangala, L. S., Lee, J. W., Shahzad, M. M. K., Kim, H. S., Shen, D., Nam, E. J., Mora, E. M., Stone, R. L., Lu, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0005 · Cited by 282
Selective Tumor Cell Targeting Using Low-Affinity, Multivalent Interactions
Carlson, C. B., Mowery, P., Owen, R. M., Dykhuizen, E. C., & Kiessling, L. L. (2007) · ACS Chemical Biology · doi:10.1021/cb6003788 · Cited by 270
The Functions and Applications of RGD in Tumor Therapy and Tissue Engineering
Wang, F., Li, Y., Shen, Y., Wang, A., Wang, S., & Xie, T. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140713447 · Cited by 259
Delfi, M., Sartorius, R., Ashrafizadeh, M., Sharifi, E., Zhang, Y., De Berardinis, P., Zarrabi, A., Varma, R. S., Tay, F. R., Smith, B. R., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101119 · Cited by 253
Gessner, I., & Neundorf, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072536 · Cited by 212
Liposome imaging agents in personalized medicine
Petersen, A. L., Hansen, A. E., Gabizon, A., & Andresen, T. L. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.003 · Cited by 164
The Rise and Rise of Stealth Nanocarriers for Cancer Therapy: Passive Versus Active Targeting
Huynh, N. T., Roger, E., Lautram, N., Benoît, J.-P., & Passirani, C. (2010) · Nanomedicine · doi:10.2217/nnm.10.113 · Cited by 164
Zhao, X., Li, L., Zhao, Y., An, H., Cai, Q., Lang, J., Han, X., Peng, B., Fei, Y., Liu, H., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201908185 · Cited by 147
RGD peptide-based non-viral gene delivery vectors targeting integrin α v β 3 for cancer therapy
Fu, S., Xu, X., Ma, Y., Zhang, S., & Zhang, S. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2018.1455841 · Cited by 139
Peptide Receptor Radionuclide Therapy: An Overview
Dash, A., Chakraborty, S., Pillai, M. R. A., & Knapp, F. F. (. (2015) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1741 · Cited by 128
Iron oxide-loaded nanotheranostics: major obstacles to in vivo studies and clinical translation
Schleich, N., Danhier, F., & Préat, V. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.024 · Cited by 124
Application of nanoparticles on diagnosis and therapy in gliomas.
Hernández-Pedro, N. Y., Rangel-López, E., Magaña-Maldonado, R., de la Cruz, V. P., Santamaría del Angel, A., Pineda, B., & Sotelo, J. (2013) · BioMed Research International · doi:10.1155/2013/351031 · Cited by 84
Amin, M., Mansourian, M., Koning, G. A., Badiee, A., Jaafari, M. R., & ten Hagen, T. L. M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.039 · Cited by 83
Fu, L., Sun, C., & Yan, L. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/am508291k · Cited by 78
Effect of PEGylation on Ligand-Targeted Magnetoliposomes: A Missed Goal
Estelrich, J., Busquets, M. A., & del Carmen Morán, M. (2017) · ACS Omega · doi:10.1021/acsomega.7b00778 · Cited by 17
Li, X., Wang, C., Liu, J., Deng, G., Deng, Y., Hu, F., Wang, Y., & Zhou, D. (2025) · Advanced Science · doi:10.1002/advs.202415133 · Cited by 8
Metadata
- Authors
- Temming, K., Schiffelers, R. M., Molema, G., & Kok, R. J.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2005-12
- Volume
- 8
- Issue
- 6
- Pages
- 381-402
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W2121357123
- Cited by
- 467
- References
- 128
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.